Regeneron To Buy 23andMe For $256M
Digest more
Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; Regeneron pledges privacy com
Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the company faces layoffs and office closure due to financial struggles and a past cyberattack.
Explore more